CGEM
CGEM
US2300311063
Cullinan Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue -- --
--
Cost of Revenue -- --
--
Gross Profit -- --
--
241.648.000 196.919.000
22.7%
Operating Income -241.648.000 -196.919.000
22.7%
Pretax Income -219.879.000 -167.458.000
31.3%
Net Income Common Stockholders -219.879.000 -167.383.000
31.4%
-- --
--
-- --
--
ende